Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct

Gabriela Pavlinkova, Barbara J M Booth, Surinder Kumar Batra, David Colcher

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Progress in the use of monoclonal antibodies (MAbs) for the treatment of solid tumors is limited by a number of factors, including poor penetration of the labeled IgG molecule into the tumors, their inability to reach the tumor in sufficient quantities without significant normal tissue toxicity, and the development of a human antimouse antibody response to the injected MAb. One possible way to alter the pharmacology of antibodies is via the use of smaller molecular weight antibody fragments called single-chain Fvs (scFvs). A divalent construct of MAb CC49, CC49 (scFv)2, composed of two noncovalently associated scFvs, was generated and shown to bind a tumor- associated antigen (TAG-72) epitope with a similar binding affinity to that of the murine IgG. The therapeutic potential of this construct after labeling with 131I was examined in athymic mice bearing established s.c. human colon carcinoma (LS-174T) xenografts. Treatment groups (n = 10) received a single dose of 131I-labeled CC49 (scFv)2 (500-2000 μCi) or 131I- labeled CC49 IgG (250 and 500 μCi). The group of mice treated with the lowest dose of 131-(scFv)2 (500 μCi) showed statistically significant prolonged survival, compared with controls (P = 0.036). Complete tumor regression was observed in 20% of mice given 1500 μCi of labeled (scFv)2 and 30 and 60% of mice treated with 250 and 500 μCi of labeled IgG, respectively. In conclusion, the CC49 (scFv)2 construct provides a promising delivery vehicle for therapeutic applications.

Original languageEnglish (US)
Pages (from-to)2613-2619
Number of pages7
JournalClinical Cancer Research
Volume5
Issue number9
StatePublished - Sep 1 1999

Fingerprint

Radioimmunotherapy
Single-Chain Antibodies
Heterografts
Colonic Neoplasms
Immunoglobulin G
Neoplasms
Immunoglobulin Fragments
Human Development
Therapeutics
Nude Mice
Antibody Formation
Epitopes
Colon
Molecular Weight
Monoclonal Antibodies
Pharmacology
Carcinoma
Survival
Antibodies
tumor-associated antigen 72

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. / Pavlinkova, Gabriela; Booth, Barbara J M; Batra, Surinder Kumar; Colcher, David.

In: Clinical Cancer Research, Vol. 5, No. 9, 01.09.1999, p. 2613-2619.

Research output: Contribution to journalArticle

Pavlinkova, Gabriela ; Booth, Barbara J M ; Batra, Surinder Kumar ; Colcher, David. / Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. In: Clinical Cancer Research. 1999 ; Vol. 5, No. 9. pp. 2613-2619.
@article{3310616e67974c6a8685f09e2e1ab7f7,
title = "Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct",
abstract = "Progress in the use of monoclonal antibodies (MAbs) for the treatment of solid tumors is limited by a number of factors, including poor penetration of the labeled IgG molecule into the tumors, their inability to reach the tumor in sufficient quantities without significant normal tissue toxicity, and the development of a human antimouse antibody response to the injected MAb. One possible way to alter the pharmacology of antibodies is via the use of smaller molecular weight antibody fragments called single-chain Fvs (scFvs). A divalent construct of MAb CC49, CC49 (scFv)2, composed of two noncovalently associated scFvs, was generated and shown to bind a tumor- associated antigen (TAG-72) epitope with a similar binding affinity to that of the murine IgG. The therapeutic potential of this construct after labeling with 131I was examined in athymic mice bearing established s.c. human colon carcinoma (LS-174T) xenografts. Treatment groups (n = 10) received a single dose of 131I-labeled CC49 (scFv)2 (500-2000 μCi) or 131I- labeled CC49 IgG (250 and 500 μCi). The group of mice treated with the lowest dose of 131-(scFv)2 (500 μCi) showed statistically significant prolonged survival, compared with controls (P = 0.036). Complete tumor regression was observed in 20{\%} of mice given 1500 μCi of labeled (scFv)2 and 30 and 60{\%} of mice treated with 250 and 500 μCi of labeled IgG, respectively. In conclusion, the CC49 (scFv)2 construct provides a promising delivery vehicle for therapeutic applications.",
author = "Gabriela Pavlinkova and Booth, {Barbara J M} and Batra, {Surinder Kumar} and David Colcher",
year = "1999",
month = "9",
day = "1",
language = "English (US)",
volume = "5",
pages = "2613--2619",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct

AU - Pavlinkova, Gabriela

AU - Booth, Barbara J M

AU - Batra, Surinder Kumar

AU - Colcher, David

PY - 1999/9/1

Y1 - 1999/9/1

N2 - Progress in the use of monoclonal antibodies (MAbs) for the treatment of solid tumors is limited by a number of factors, including poor penetration of the labeled IgG molecule into the tumors, their inability to reach the tumor in sufficient quantities without significant normal tissue toxicity, and the development of a human antimouse antibody response to the injected MAb. One possible way to alter the pharmacology of antibodies is via the use of smaller molecular weight antibody fragments called single-chain Fvs (scFvs). A divalent construct of MAb CC49, CC49 (scFv)2, composed of two noncovalently associated scFvs, was generated and shown to bind a tumor- associated antigen (TAG-72) epitope with a similar binding affinity to that of the murine IgG. The therapeutic potential of this construct after labeling with 131I was examined in athymic mice bearing established s.c. human colon carcinoma (LS-174T) xenografts. Treatment groups (n = 10) received a single dose of 131I-labeled CC49 (scFv)2 (500-2000 μCi) or 131I- labeled CC49 IgG (250 and 500 μCi). The group of mice treated with the lowest dose of 131-(scFv)2 (500 μCi) showed statistically significant prolonged survival, compared with controls (P = 0.036). Complete tumor regression was observed in 20% of mice given 1500 μCi of labeled (scFv)2 and 30 and 60% of mice treated with 250 and 500 μCi of labeled IgG, respectively. In conclusion, the CC49 (scFv)2 construct provides a promising delivery vehicle for therapeutic applications.

AB - Progress in the use of monoclonal antibodies (MAbs) for the treatment of solid tumors is limited by a number of factors, including poor penetration of the labeled IgG molecule into the tumors, their inability to reach the tumor in sufficient quantities without significant normal tissue toxicity, and the development of a human antimouse antibody response to the injected MAb. One possible way to alter the pharmacology of antibodies is via the use of smaller molecular weight antibody fragments called single-chain Fvs (scFvs). A divalent construct of MAb CC49, CC49 (scFv)2, composed of two noncovalently associated scFvs, was generated and shown to bind a tumor- associated antigen (TAG-72) epitope with a similar binding affinity to that of the murine IgG. The therapeutic potential of this construct after labeling with 131I was examined in athymic mice bearing established s.c. human colon carcinoma (LS-174T) xenografts. Treatment groups (n = 10) received a single dose of 131I-labeled CC49 (scFv)2 (500-2000 μCi) or 131I- labeled CC49 IgG (250 and 500 μCi). The group of mice treated with the lowest dose of 131-(scFv)2 (500 μCi) showed statistically significant prolonged survival, compared with controls (P = 0.036). Complete tumor regression was observed in 20% of mice given 1500 μCi of labeled (scFv)2 and 30 and 60% of mice treated with 250 and 500 μCi of labeled IgG, respectively. In conclusion, the CC49 (scFv)2 construct provides a promising delivery vehicle for therapeutic applications.

UR - http://www.scopus.com/inward/record.url?scp=0032862227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032862227&partnerID=8YFLogxK

M3 - Article

C2 - 10499640

AN - SCOPUS:0032862227

VL - 5

SP - 2613

EP - 2619

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -